Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05347732
Other study ID # 341357
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 25, 2022
Est. completion date January 3, 2035

Study information

Verified date March 2023
Source Oslo University Hospital
Contact Ragnhild Helseth, MD PhD
Phone +47 97 14 95 18
Email ramhel@ous-hf.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this observational study is to assess why thrombolytic treatment with tissue-plasminogen activator (t-PA) fails in patients with acute ST-segment elevation myocardial infarction (STEMI). The study will include 200 STEMI patients at the time of arrival at Oslo University Hospital Ullevål after receiving prehospital thrombolysis. A blood sample will be taken immediately for the study of factors related to coagulation, fibrinolysis and inflammation. Levels of the biomarkers will be compared between patients with successful and failed thrombolysis.


Description:

This study aims to explore why thrombolytic treatment with tissue-plasminogen activator (t-PA) fails in up to 50 % of pasients with acute ST-segment elevation myocardial infarction (STEMI). This is important in Norway due to the long geographic distances and the fact that up to 70 % of STEMI patients in some Norwegian areas receive thrombolysis in stead of primary, invasive revascularization with percutaneous coronary intervention (PCI). Today, no well-defined biomarker or score can predict the successfulness of thrombolytic therapy during STEMI. As failed thrombolysis leads to larger myocardial infarctions and poorer outcome, defining factors for improved risk stratification is important. The TROFAMI study is a prospective study which will include 200 STEMI patients given prehospital thrombolysis. A blood sample will be taken immediately after hospital admission for the analysis of potential relevant biomarkers related to coagulation, fibrinolysis and inflammation. The biomarkers will be evaluated against the successfullness or not of thrombolysis. Oslo University Hospital is the largest STEMI center in Norway. Each year, approximately 100 STEMI patients given prehospital thrombolysis are hospitalized at UllevÄl. The inclusion is anticipated to take place during the time period 2022-2024.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 3, 2035
Est. primary completion date April 25, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: STEMI patients > 18 years given prehospital thrombolysis. Exclusion Criteria: None.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Successfull thrombolysis
Biomarker levels will be compared between patients with successful and failed thrombolysis.

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Failed thrombolysis Persistent chest pain and/or < 50 % ST segment resolution Decided immediately after hospital admission.
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Terminated NCT04542889 - Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction N/A
Recruiting NCT04951856 - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Phase 4
Terminated NCT04459299 - CorPath GRX STEMI Study
Recruiting NCT05557019 - Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study N/A
Completed NCT03527940 - Prognostic Markers of Patients With STEMI
Not yet recruiting NCT03264859 - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction N/A
Not yet recruiting NCT03182855 - Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI Phase 4
Not yet recruiting NCT03266289 - Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab N/A
Withdrawn NCT04566289 - Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
Completed NCT04289012 - HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study N/A
Not yet recruiting NCT04185077 - Bivalirudin in Late PCI for Oatients With STEMI Phase 4
Completed NCT03609346 - Asian Registry of the BioFreedom Stent for STEMI Patients
Recruiting NCT05107076 - Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
Recruiting NCT02998853 - Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure N/A
Completed NCT03677180 - National Cardiogenic Shock Initiative
Completed NCT03507777 - ILUMIEN IV: OPTIMAL PCI N/A
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Completed NCT03070496 - Multicenter Cohort of STEMI Patients N/A
Active, not recruiting NCT03874338 - CLEAR SYNERGY Neutrophil Substudy